Sanofi Announces $20 Billion Investment in US R&D and Manufacturing by 2030
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its intention to invest at least $20...
NASDAQ: SNY
Sanofi’s Opella Becomes Independent Consumer Healthcare Company After CD&R Deal
Opella, the consumer health business of French pharmaceutical giant Sanofi (NASDAQ: SNY), became an independent...
Innate Pharma and Sanofi Restructure 2016 Research Agreement on CD123 ANKET Drug
France-based Innate Pharma SA has announced a significant adjustment to its 2016 research and licensing...
Sanofi Reports Q1 Sales Growth Driven by Dupixent and New Product Launches
French pharmaceutical giant Sanofi (NASDAQ: SNY) released its Q1 2025 financial results, reporting global net...
Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria
France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...
Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...
Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received Orphan Drug Designation (ODD) from...
Sanofi and Cathay Capital Launch RMB 2 Billion Pharma Innovation Fund in China
The Sanofi Cathy Capital Pharmaceutical Innovation Fund, a joint venture between French pharmaceutical giant Sanofi...
Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program
US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership...
Sanofi’s Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received approval from Japan’s Ministry of...
Sanofi’s Qfitlia Approved by FDA for Hemophilia A and B Prophylaxis
France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval from the US Food...
Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from...
Sanofi’s Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis
Sanofi (EPA: SAN, NASDAQ: SNY) announced that a market filing for its tolebrutinib as a...
Opella and JD Healthcare Collaborate to Enhance Fatty Liver Awareness in China
Opella, the consumer health business of French giant Sanofi (EPA: SAN, NASDAQ: SNY), held a...
Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager...
Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy
Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...
Sanofi’s Dupixent Receives Priority Review from FDA for Bullous Pemphigoid Treatment
Sanofi (EPA: SAN, NASDAQ: SNY) announced that the US Food and Drug Administration (FDA) has...
Sanofi and J&J’s E. coli Vaccine Fails Phase III Study
France-based Sanofi (NASDAQ: SNY) and US giant Johnson & Johnson’s (J&J, NYSE: JNJ) vaccine candidate...
Sanofi Reports Strong Q4 Growth, Plans EUR 5 Billion Share Buyback
French pharmaceutical giant Sanofi (NASDAQ: SNY) reported a strong fourth-quarter performance with 10.3% year-on-year (YOY)...